Lilly Asia Ventures - Backing the Innovation of China's Biomedical Industry

SHANGHAI, Dec.17, 2015 /PRNewswire/ – Recently, Biodiscover, an independent biomedical media company, ranked the top ten innovative biopharmaceutical companies in China. 4 out of 10 top companies are captured in Lilly Asia Ventures (LAV)'s portfolio, including Chipscreen, Innovent, Betta Pharma and 3S Bio (The other six companies are Hengrui, Luye, Kanghong, Ascletis, Simcere, and Hutchinson. Source: http://www.biodiscover.com/news/report/122364.html)
"We are proud of this result and honored to have supported four of the ten frontrunners in China healthcare innovation," commented Dr. Yi Shi, LAV's Managing Partner. "This list reflects our expertise in biomedical industry and validates our investment strategy - we bet on solid science and exceptional management team and leverages our domain expertise and resources to create value for portfolio companies post investment."
Founded in 2008 and headquartered in Shanghai, LAV has invested in over 30 companies globally, with strong focus on China. LAV's portfolio covers all major sectors of the biomedical and healthcare industry including biopharmaceuticals, medical devices, diagnostics and healthcare services.
"Looking ahead, we are blessed with a quickly expanding talent pool, favorable innovation and funding environment, and strong government support. The best is yet to come." Dr. Shi remains optimistic of China biomedical market: "LAV will continue partnering with ambitious entrepreneurs with high integrity, helping them develop and commercialize high quality medical products that contribute to global health."
CONTACT: 

Nicole Liu
[email protected]
+86-21-63406179
Website: www.lillyasiaventures.com
Source: prnewswire.com
 

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.